736 related articles for article (PubMed ID: 22526913)
1. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.
Hughes DT; Miller BS; Cohen MS; Doherty GM; Gauger PG
Ann Surg Oncol; 2014 May; 21(5):1647-52. PubMed ID: 24385210
[TBL] [Abstract][Full Text] [Related]
3. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
[TBL] [Abstract][Full Text] [Related]
4. Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation.
Park DJ; Lim JA; Kim TH; Choi HS; Ahn HY; Lee EK; Lee YJ; Kim KW; Park YJ; Yi KH; Cho BY
Endocr J; 2012; 59(11):1021-30. PubMed ID: 22814366
[TBL] [Abstract][Full Text] [Related]
5. Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma.
Farrag TY; Agrawal N; Sheth S; Bettegowda C; Ewertz M; Kim M; Tufano RP
Head Neck; 2007 Dec; 29(12):1069-74. PubMed ID: 17563908
[TBL] [Abstract][Full Text] [Related]
6. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma.
Lee HS; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
World J Surg; 2015 Aug; 39(8):1943-50. PubMed ID: 25820911
[TBL] [Abstract][Full Text] [Related]
8. Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases.
O'Neill CJ; Coorough N; Lee JC; Clements J; Delbridge LW; Sippel R; Sywak MS; Chen H; Sidhu SB
ANZ J Surg; 2014 Apr; 84(4):240-4. PubMed ID: 23316684
[TBL] [Abstract][Full Text] [Related]
9. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
[TBL] [Abstract][Full Text] [Related]
10. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.
Alzahrani AS; Raef H; Sultan A; Al Sobhi S; Ingemansson S; Ahmed M; Al Mahfouz A
J Endocrinol Invest; 2002 Jun; 25(6):526-31. PubMed ID: 12109624
[TBL] [Abstract][Full Text] [Related]
11. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
Mourão GF; Rosario PW; Calsolari MR
Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients.
Gambardella C; Tartaglia E; Nunziata A; Izzo G; Siciliano G; Cavallo F; Mauriello C; Napolitano S; Thomas G; Testa D; Rossetti G; Sanguinetti A; Avenia N; Conzo G
World J Surg Oncol; 2016 Sep; 14(1):247. PubMed ID: 27644091
[TBL] [Abstract][Full Text] [Related]
13. Postablation stimulated thyroglobulin level is an important predictor of biochemical complete remission after reoperative cervical neck dissection in persistent/recurrent papillary thyroid carcinoma.
Lang BH; Wong KP; Wan KY
Ann Surg Oncol; 2013 Feb; 20(2):653-9. PubMed ID: 22956067
[TBL] [Abstract][Full Text] [Related]
14. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
15. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
[TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
[TBL] [Abstract][Full Text] [Related]
17. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
18. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
19. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
20. Papillary thyroid cancer: medical management and follow-up.
Kloos RT
Curr Treat Options Oncol; 2005 Jul; 6(4):323-38. PubMed ID: 15967085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
